Genetown
Filter News
Found 54,235 articles
-
Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.
-
Cadent Therapeutics secured $40 million to advance its lead program, CAD-1883.The company also struck a deal with Novartis to develop NMDA modulators.
-
Beam Therapeutics Appoints Carole Ho, M.D., to Board of Directors
11/15/2018
Dr. Ho brings to Beam more than 15 years of life sciences experience as a clinical neurologist, neuroscientist and leader in biopharmaceutical drug development.
-
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
11/15/2018
Boehringer Ingelheim Expands Biomarker-driven Oncology Programs
-
Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza A
11/15/2018
Visterra, Inc., a clinical stage biotechnology company, announced today that its Phase 2a study of VIS410, a novel monoclonal antibody, demonstrated safety, tolerability and clinical activity trends in non-hospitalized patients with influenza A.
-
Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
11/15/2018
84% ORR in PDGFRα D842V GIST and 20% ORR in fourth-line or later GIST support plans to submit New Drug Application to FDA in the first half of 2019
-
AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®
11/15/2018
The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® as a first line treatment of adult patients with advanced renal cell carcinoma
-
United Spinal Association Issues Recommendation for Insurers to Consider Powered Exoskeleton Devices Medically Necessary for Paralyzed Individuals
11/15/2018
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") applauds United Spinal Association's recommendation, dated November 9, 2018, that health insurance providers consider the use of powered exoskeleton devices as medically necessary for eligible individuals with spinal cord injuries
-
Copyright Clearance Center Announces Enhancements to Award-Winning Content Workflow Solution, RightFind®
11/15/2018
Copyright Clearance Center, Inc. (CCC), a leader in advancing copyright, accelerating knowledge, and powering innovation, announces enhancements to its award-winning content workflow solution, RightFind®, making it even easier to use than ever before, giving scientific research organizations access to content they need – anytime, anywhere.
-
Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology
11/15/2018
Pulmatrix. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently completed phase 1/1b clinical trial of Pulmazole, an inhaled dry-powder iSPERSE™ formulation of itraconazole, at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.
-
Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors
11/15/2018
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors.
-
New Harmonized Outcome Measures for Atrial Fibrillation Published in HeartRhythm
11/15/2018
OM1, a leading health outcomes and technology company, today announced the publication of new harmonized outcome measures for atrial fibrillation (AF) in HeartRhythm.
-
bluebird bio to Present at the Evercore ISI HealthCONx Conference
11/15/2018
bluebird bio (Nasdaq: BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.m. ET at the Boston Harbor Hotel, Boston.
-
Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
11/15/2018
Mr. Cumbo, biotech industry veteran, brings commercial expertise and strategic leadership in industry-leading commercial product launches
-
Flagship Pioneering Names Ryan Watts, CEO of Denali Therapeutics, as Recipient of the 2018 Pioneering Leader Award
11/15/2018
Flagship Pioneering today announced the recipient of the firm's annual Pioneering Leader Award.
-
Lyndra Therapeutics Reports Positive Results from Pharmacokinetics (PK) Study of its Ultra-long-acting Oral Dosage Form
11/15/2018
Study shows viability of taking once-weekly pill
-
Entrinsic Health Solutions and Nestlé Health Science Enter Global Partnership for Novel Amino Acid Product enterade®
11/15/2018
Entrinsic Health Solutions (EHS), an innovative health sciences company, today announced that they have entered into a partnership with Nestlé Health Science (NHSc), a global innovative leader pioneering premium-quality, science-based nutritional health solutions.
-
Accelerated Cure Project Announces Collaboration with National Multiple Sclerosis Society
11/15/2018
Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) today announced a collaboration with the National Multiple Sclerosis Society (Society) to speed the pace of research for cures and treatments for MS.
-
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
-
Two weeks after acquiring two drugs from AstraZeneca in a $700 million deal, Germany-based Grünenthal flexed its M&A muscle again to acquire Averitas Pharma to extend its commercial footprint in the United States.